Vaxdyn and the University of Latvia have obtained funding from the EUROSTARS program to prepare prevention strategies for diseases caused by antibiotic-resistant bacteria.
They receive a grant of half a million euros to prepare the clinical and commercial strategy for vaccination against Klebsiella pneumoniae and Acinetobacter baumannii bacteria.
The research consortium led by Vaxdyn, comprising the vaccine company and the University yof Latvia, has been awarded a grant of 647,000 euros to develop the clinical and commercial vaccination strategy against Klebsiella pneumoniae and Acinetobacter baumannii. These are two of the main antibiotic-resistant bacteria for which the World Health Organization has identified an urgent need for preventive vaccines.
The grant to Vaxdyn, amounting to 397,000 euros, was approved in the Interempresas call of CDTI, following a positive decision by the European Commission.
The project will involve an assessment of the epidemiology of the population affected by these bacteria at the Paul Stradins University Hospital in Riga, Latvia's reference hospital. Vaxdyn will confirm that the circulating bacteria among patients are covered by the immunity generated by the K-Vax vaccine under development, which is showing universal coverage. The project's most ambitious goal is to define the strategy for conducting clinical efficacy trials of the vaccine and the strategy for using the vaccine once approved to create the greatest value for society. The project, which will be carried out between 2023 and 2026, is led by Vaxdyn's director, Dr. Juan José Infante, and the renowned infectious disease expert Dr. Uga Dumpis, head of infectious diseases at Paul Stradins Hospital.